The majority of promotional expenditures are invested in drug samples, one of the industry’s most important marketing tactics ...
When the sole manufacturer withdrew a critical cancer drug from Medicare and Medicaid, patients were left without options.
In late August 2025, CMS released Performance Year (PY) 2024 data for the Medicare Shared Savings Program (MSSP). This marked ...
The 340B rebate pilot model set to begin in January 2026 starkly presents the key tradeoff between program integrity and ...
The real gold standard for science, and academic freedom, requires upholding scientific work that investigates who and what ...
A 2026 CMS proposed rule contains multiple provisions that will improve the transparency of hospital prices and support the ...
The Inflation Reduction Act (IRA) of 2022 mandates price negotiations for certain drugs under Medicare, shortening the exclusivity period historically used to recoup research and development ...
The No UPCODE Act—with some refinements—is a good start insofar it establishes some key pieces of reform, but a broader ...
With collaboration and evidence-based approaches, we can build a patient-centric health care system that works better for ...
Abandoning a universal recommendation, in place since 2021, in favor of shared clinical decision making for everyone. This ...
Despite the promise of compassionate release as a humanitarian and cost-saving action, a staggeringly low number of people ...
After a summer hiatus, bird flu cases are once again ticking up in the United States. We are flying blind in the face of a potentially catastrophic pandemic threat.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback